Merck, Ra Pharma enter drug-development deal worth up to $200M

04/2/2013 | Pharmaceutical Business Review Online · Xconomy

Merck and Ra Pharmaceuticals agreed to collaborate in the development of Cyclomimetics drug candidates against multiple therapeutic areas using the latter's Extreme Diversity platform. Cyclomimetics are peptidelike molecules that have the diversity and specificity of antibodies. The deal entitles Ra to about $200 million in payments including upfront fee, research funding and milestone fees.

View Full Article in:

Pharmaceutical Business Review Online · Xconomy

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN